The p53 tumor suppressor coordinates a series of antiproliferative responses that restrict the expansion of malignant cells, and as a consequence, p53 is lost or mutated in the majority of human cancers. Here, we show that p53 restricts expression of the stem and progenitor-cell-associated protein nestin in an Sp1/3 transcription-factor-dependent manner and that Nestin is required for tumor initiation in vivo. Moreover, loss of p53 facilitates dedifferentiation of mature hepatocytes into nestin-positive progenitor-like cells, which are poised to differentiate into hepatocellular carcinomas (HCCs) or cholangiocarcinomas (CCs) in response to lineage-specific mutations that target Wnt and Notch signaling, respectively. Many human HCCs and CCs show elevated nestin expression, which correlates with p53 loss of function and is associated with decreased patient survival. Therefore, transcriptional repression of Nestin by p53 restricts cellular plasticity and tumorigenesis in liver cancer.
INTRODUCTION
p53 mutations occur in a wide range of human cancers and are often associated with aggressive tumor behavior and poor patient prognosis (Spike and Wahl, 2011) . Wild-type p53 is activated by DNA damage and various forms of oncogenic stress, during which it induces genes that promote cell-cycle blockade, apoptosis, senescence, differentiation, and/or autophagy-various aspects of cell metabolism (Vousden and Lane, 2007) -and can even suppress epigenetic reprogramming of differentiated cells into induced pluripotent stem (IPS) cells (Hong et al., 2009; Kawamura et al., 2009; Marió n et al., 2009 ). In addition to its cell-autonomous activities, p53 can promote the secretion of a variety of factors that influence the tissue microenvironment in a non-cell-autonomous manner (Lujambio et al., 2013) . Which of these p53 activities is most relevant for its tumor suppressor role has been widely debated and is likely context dependent (Kenzelmann Broz and Attardi, 2010) . p53 promotes transcriptional activation through the recruitment of chromatin-modifying proteins to the promoters of genes with p53 response elements, and indeed, key p53 target genes contribute to specific effector functions (Vousden and Prives, 2009) . p53 can also repress gene expression through mechanisms that are less well understood. p53 can directly repress transcription by binding p53 response elements in, for example, the Nanog or CD44 promoters (Godar et al., 2008; Lin et al., 2005) or indirectly either by inducing genes such as p21, E2F7, and miR-34 that act through transcriptional or posttranscriptional mechanisms or by antagonizing the basal transcription machinery and/or transcriptional activators, such as Sp1 and ETS1 (Ho and Benchimol, 2003) . Regardless, the contribution of this p53 property to tumor suppression is not clear.
p53 mutations are common in primary liver cancers, which represent the fifth-most frequent tumor type worldwide (Hussain et al., 2007) . These tumors present as either hepatocellular carcinoma (HCC) or intrahepatic cholangiocarcinoma (CC) and can easily be distinguished histologically and by assessing expression of lineage-specific markers. HCC typically consists of polygonal cells growing in a solid-trabecular growth pattern, whereas CC often displays a ductal morphology with a substantial stromal reaction. Although the mutational profiles of HCC and CC are distinct, p53 mutations occur in both tumor types and are associated with a particularly poor prognosis (Hussain et al., 2007; Nault and Zucman-Rossi, 2011) . Studies in mouse models indicate that p53 inactivation is required for the maintenance of murine liver carcinomas in vivo (Xue et al., 2007) . Still, how p53 acts to limit the development of primary liver cancers remains poorly understood.
Though it is commonly assumed that HCC and CC arise through malignant transformation of resident hepatocytes and cholangiocytes, respectively, the cell of origin of each disease is controversial. For example, some studies suggest that cholangiocarcinoma can arise through transdifferentiation of adult hepatocytes to cholangiocytes (Fan et al., 2012; Sekiya and Suzuki, 2012) , whereas others imply that each tumor type can arise from bi-potential progenitor cells residing in the adult liver (Roskams, 2006) . Consistent with the latter view, rare liver tumors show a mixed HCC/CC histopathology.
The class IV intermediate filament protein Nestin has been identified as a marker of bi-potential liver progenitor cells (oval cells) that reside in the adult liver and expand upon chronic liver damage (Gleiberman et al., 2005) . Nestin is highly expressed in the mammalian brain and is frequently used as a marker of neuronal stem cells (Mignone et al., 2004) . In glioma, Nestinpositive cells are crucial for tumor initiation and maintenance and mark a stem-cell-like population that is necessary to propagate disease . Here, we show that p53 can repress Nestin through an indirect mechanism that restricts tumorigenesis by limiting cellular plasticity and the expansion of progenitor-like populations in response to oncogenic stress. Consequently, p53 loss, together with lineage-specific lesions, enables the emergence of either HCC or CC with progenitorlike properties that, in patients, are associated with reduced survival. Our results suggest that the ability of p53 to restrict the ''reprogramming'' of differentiated cells into a more pluripotent state contributes to its tumor suppressive role.
RESULTS

p53 Deletion Leads to Mixed Lineage Tumors with High Nestin Expression
Conditional p53 deletion in the murine liver (using the albumin promoter combined with a-fetoprotein enhancer [Alfp-cre]) produces tumors with a mixed HCC/CC histology (Katz et al., 2012) ( Figure 1A ). To determine whether these tumors express the progenitor cell marker nestin, we performed immunostaining with an antibody specifically recognizing the murine Nestin protein. Surprisingly, high Nestin expression was identified in both the HCC and the CC components ( Figure 1B) . Moreover, some Nestin-positive cells were identified in adjacent peritumoral tissue ( Figure 1C ), indicating expansion of noncancerous Nestin-positive cells. By contrast, chemically induced liver tumors produced by the carcinogen diethylnitrosamine (DEN), which rarely contain p53 mutations (Rumsby et al., 1994) , did not express Nestin (Figure 1D and 1E) . Similarly, Nestin mRNA levels were significantly higher in p53 null mixed HCC/CC tumors compared to DENinduced HCCs ( Figure 1F ). Thus, liver-specific p53 deletion triggers the formation of bi-lineage liver tumors with high Nestin expression.
Nestin Levels are High in Human Tumors, where They Correlate with Poor Patient Prognosis As a first step toward understanding factors that influence Nestin expression in liver cancers, we examined Nestin expression in human liver tumor cell lines using the cancer cell line encyclopedia database. As observed above, cell lines with p53 mutation or genomic loss at the p53 locus show higher Nestin mRNA levels than those with wild-type p53 (Figure 2A ). These results were confirmed by nestin IHC on 88 primary HCCs with different etiology (Table S1 available online) and 47 primary human CCs (Tables S2 and S3 ). Hence, 17% of the HCCs and 40% of the CCs exhibited Nestin-positive tumor cells (Figures 2B and S1A) . In contrast, Nestin protein was not expressed in hepatocytes of healthy livers and could only be detected in endothelial cells of blood vessels ( Figure 2B ). Additionally, Nestin mRNA levels were significantly higher in HCCs and CCs compared to surrounding liver tissue (data not shown and Figure S1B ). We also analyzed a small number of human tumors with mixed HCC/CC histopathology and noted a trend for higher Nestin expression in those classified with ''stem cell features'' (2/3) compared to those with classical HCC/CC histopathology (1/5) ( Figure S1D ). Importantly, patients harboring tumors with high Nestin levels displayed a much worse clinical outcome, with a median survival of 10 months compared to 29 months for patients with nestin-negative tumors ( Figure 2C ). Therefore, like p53 mutations, Nestin is overexpressed in a subset of all liver cancer types, where it is associated with poor patient prognosis.
We next compared p53 status as assessed by array-based CGH and/or sequencing of p53 exons 5-8 to nestin expression, as determined from publicly available transcriptional profiling data (Neumann et al., 2012) . Nestin levels were significantly higher in HCC samples that displayed p53 mutations or reduced copy number at the p53 locus ( Figures 2D, 2E , and S2C). One particularly informative HCC sample harbored a single Nestinpositive nodule in an otherwise multifocal tumor ( Figure 2F ). Remarkably, DNA sequencing of microdissected tissue revealed a p53 S249A mutation in the Nestin-positive nodule, whereas all of the Nestin-negative nodules harbored wild-type p53 (Figure 2F) . These studies support a direct relationship between loss of p53 and Nestin expression in human liver cancer.
p53 Represses Nestin Transcription
We next investigated the molecular basis underlying the relationship between p53 status and nestin expression in the liver. To report Nestin transcription, we used a transgenic mouse in which activation of the Nestin promoter drives expression of green fluorescent protein (GFP) (Gleiberman et al., 2005) . Analysis of adult liver tissues revealed GFP expression limited to individual cells within the interlobular bile duct and the canal of Hering ( Figure S2A )-the suspected location of the liver progenitor cell niche in the adult (Fellous et al., 2009 ). Immunofluorescence staining indicated that expression of the liver progenitor cell markers A6 and EpCAM overlapped with the Nestin-driven GFP, whereas expression of the hepatocyte markers CK8 and asialoglycoprotein receptor (HR) did not (Figure S2B ). These observations reinforce the notion that, in normal livers, Nestin is expressed in undifferentiated progenitor cell populations.
To determine whether there was a direct relationship between p53 and Nestin expression during liver tumorigenesis, we took advantage of a liver carcinoma model that we previously used to establish a role for p53 in tumor maintenance (Xue et al., 2007) . We isolated E12-15 liver progenitor cells (LPCs) from fetal Nestin promoter-GFP mice and infected them with retroviruses coexpressing different oncogenes (H-Ras G12D , Myc, or Yap S127A ), each coupled to a tetracycline transactivator (tTA) that drives reversible shRNA expression. These vectors were coexpressed with a second retrovirus containing a doxycycline-regulated shRNA targeting p53 (schematized in Figure 3A ). Modified fetal liver cells were injected into livers of recipient mice, and after tumor onset, the mice were fed a Doxycycline (Dox)-containing diet to silence the shRNA and reactivate p53. After 8 days, tumor tissue was isolated and analyzed for GFP expression using immunoblotting of liver extracts or by immunofluorescence of tissue sections.
Whereas the parental hepatoblast populations were negative for GFP expression (data not shown), tumors with p53 depletion (off-Dox) showed a strong GFP signal irrespective of the driving oncogene, suggesting that p53 suppression derepressed the Nestin promoter or, alternatively, selected for a subset of cells with intrinsically high Nestin levels. Consistent with the former possibility, tumors re-expressing p53 following Dox addition quickly silenced GFP ( Figures 3B and 3C ). Thus, p53 can repress Nestin-promoter activity in vivo.
p53 Regulates Nestin Expression in an Sp-1/3-Dependent Manner Studies suggest that p53 can act directly to repress mRNA transcription by binding p53 response elements in target promoters or can act indirectly by transcriptionally activating genes such as , left) and p53 mutant-expressing (p53 R249S , right) tumor nodule of a multinodular HCC. p53 mutation was determined by Sanger sequencing. Scale bars, 50 mm. See also Figure S1 and Table S1 .
p21, E2F7, and miR-34 that ultimately reduce mRNA levels through transcriptional or posttranscriptional mechanisms (Ho and Benchimol, 2003) . To assess the molecular basis for p53-mediated Nestin repression in human HCC cell lines, we explored factors that influence Nestin expression in human HCC cell lines with deletion of p53 (Hep3B), harboring a Y220C mutation in p53 (HuH7) or expressing wild-type p53 (HepG2). Enforced expression of wildtype p53 (p53 WT ) caused a substantial decrease in Nestin mRNA (data not shown) and protein expression ( Figure 4A ) in Hep3B cells and HuH7 cells; conversely, suppression of wild-type p53 in HepG2 cells using RNAi caused an increase in Nestin protein levels ( Figure 4A ). Confirming the specificity of these effects, neither enforced expression of two different p53 mutants (R175H and R248W) in p53 null Hep3B cells nor knockdown of mutant p53 (R249S) in PLC cells altered Nestin expression ( Figure S3A ). Thus, p53 can repress Nestin in human HCC cells.
Using different informatics approaches, we identified a potential p53-binding site in the mouse Nestin gene (data not shown). However, this site was not conserved in the human Nestin promoter, and since p53 can suppress Nestin in human cells, we hypothesized that p53 most likely represses Nestin through an indirect mechanism. Still, its repressive effect was not mediated through p21, E2F7, or miR-34 because Huh7 cells coexpressing potent shRNAs targeting p21 or E2F7 still repressed Nestin in response to wild-type p53 ( Figure S3B ), and no predicted miR34-binding sites were found in the 3 0 UTR of the murine or human transcripts (data not shown).
Another mechanism whereby p53 can repress transcription is by antagonizing other transcriptional activators. For example, p53 can bind Sp1, leading to the repression of several Sp1-inducible genes involved in embryonic development and angiogenesis (Zhang et al., 2000) . Interestingly, the murine Nestin promoter harbors two Sp1-binding sites upstream of the transcription start site (TSS), which are conserved in the human Nestin gene and are crucial for Nestin expression (Cheng et al., 2004 ) (see also Figure S3E ). To test whether Sp1 (and its related family member Sp3) controls Nestin in HCC cells, we used siRNAs capable of knocking down either Sp1 or Sp3 and tested their ability to modulate Nestin expression in p53 mutant HuH7 cells. Although none of the Sp1 and Sp3 siRNAs were capable of potent Sp1/3 knockdown ( Figure S3C ), cosuppression of both genes substantially reduced Nestin protein ( Figure 4B ) and mRNA ( Figure S3D ) expression.
To investigate whether p53 influences the activity of the Nestin promoter via Sp1, we transfected NIH 3T3 cells with murine Nestin promoter constructs harboring intact or mutated Sp1-binding sites (Cheng et al., 2004) together with either a p53 WT expression vector or an empty vector control. Confirming the Sp1 dependence of the Nestin promoter (Cheng et al., 2004) , cells transfected with reporter construct harboring intact Sp1-binding sites (NESP À161/+183) showed luciferase activity, whereas cells harboring the construct with deleted Sp1 sites (NESP DSp1) did not ( Figure 4C ). Importantly, coexpression of p53 substantially decreased reporter output from the (legend on next page) NESP À161/+183 but had no effect on NESP DSp1 activity ( Figure 4C ). Chromatin immunoprecipitation (ChIP) experiments using antibodies directed to either Sp1 or Sp3 revealed specific binding of each protein to the consensus sites in p53 mutant human HuH7 cells. Consistent with a role for p53 in modulating this activity, enforced expression of wild-type p53 triggered a release of Sp1 and Sp3 from the Nestin promoter ( Figure 4D) . Similarly, treatment of Hep3B (p53 null) and Huh7 (p53 mutant) cells with mithramycin, a small molecule capable of binding the GC-rich regions found in Sp1-binding sites (Bond et al., 2004) , abolished Sp1/3 binding to the Nestin promoter in a dose-dependent manner ( Figure 4E, F) . Together, these results indicate that Sp1 and Sp3 bind and activate the Nestin promoter in HCC cells in a manner that is antagonized by functional p53.
Wild-type p53 can interact directly with Sp1, suggesting a way in which p53 might repress gene expression in a manner that is disrupted in cancer cells. To confirm that this interaction can occur in liver cancer cells, we cotransfected wild-type p53 into p53 mutant HuH7 cells and assessed the ability of Sp1 to coimmunoprecipitate with p53. Interestingly, the transduced wildtype p53 bound Sp1, whereas the endogenous mutant p53 did not ( Figure S3F ). Nonetheless, we could not detect p53 bound to the Nestin promoter, suggesting that this interaction with Sp1 occurs off chromatin (data not shown). p53/Sp1/3 complexes have been reported to interfere with a self-amplification process, leading to diminished Sp1/3 levels (Tapias et al., 2008) . Concordantly, we observed reduced Sp1, Sp3, and Nestin protein levels in response to p53
WT transduction into HuH7 cells ( Figure S3G ). Consistent with the role of Sp1/3 in activating nestin, Nestin mRNA expression significantly correlated with Sp1 levels in primary HCCs ( Figure 4G ) and Sp3 levels in CCs ( Figure 4H ). Therefore, p53 represses Nestin at least in part by antagonizing Sp1 and Sp3.
p53 Restricts Hepatocyte Transformation and Plasticity
To further investigate the relationship between p53 and Nestin expression in liver tumorigenesis, we used a transposon-based system that enables the production and analysis of liver carcinomas with defined genetic alterations in the mouse (Yant et al., 2000) . In this approach, plasmids harboring a recombinant Sleeping Beauty (SB) transposon vector and transposase are injected into the liver using hydrodynamic tail-vein injection, which leads to selective uptake by hepatocytes (Bell et al., 2007) . Transient expression of transposase in the transduced hepatocytes facilitates integration of the transposon vector into genomic DNA, allowing stable and heritable transgene expression. Of note, morphological and lineage-tracing studies indicate that only differentiated hepatocytes and not cholangiocytes or progenitor cells are transduced using this approach (Fan et al., 2012) . We chose to use Yap as a tumor-promoting oncogene, as it is altered in both HCC and CC and can drive hepatocellular carcinoma in orthotopic or transgenic models (Dong et al., 2007; Zender et al., 2006) . A two-vector system was used to ensure the expression of Yap together with an shRNA in the same cell: in one vector, Yap and a GFP reporter were coexpressed under the control of the inducible TREtight (TREt) promoter; in the other, the miR30 shRNA cassette was placed downstream of a reverse tetracycline transactivator (rtTA3) expressed from the constitutive EF1a promoter ( Figure 5A ). Hence, only cells receiving both vectors are capable of inducing Yap expression upon Dox addition, and then these cells can be visualized using the coexpressed GFP reporter. For these experiments, we incorporated either a control shRNA targeting Renilla firefly luciferase (shRen) or a well-characterized shRNA capable of potently suppressing p53 (shp53).
Hydrodynamic tail-vein injection was used to target the above vector combinations to the livers of FVBN mice. As anticipated from previous reports (Fan et al., 2012) , analysis of livers for GFP-positive cells shortly after transduction identified the transduced cells as HNF4a-expressing hepatocytes, and no transduced cells were observed in CK19-positive cholangiocytes. Similarly, injection of dsRed-expressing vectors into Nestin promoter-GFP mice revealed no overlap of dsRed and Nestin expression ( Figure S4A ). Six weeks after injection and Dox addition, mice receiving YAP and the control shRen transposons showed no GFP fluorescence, suggesting that these cells were eventually cleared. Accordingly, no overt pathology was observed ( Figures 5B and 5C, left) . Thus, Yap alone was unable to drive tumorigenesis over the observation period.
Livers from mice receiving the combination of Yap and a p53 shRNA displayed a dramatically different phenotype. Visual inspection and histological analyses (Figures 5B and 5C, right) revealed the presence of many GFP-positive foci consisting of small undifferentiated tumor cells that displayed markers of bi-potential liver progenitors, having weak expression of the epithelial marker CK19 and high expression of the stem cell marker CD133 (data not shown). These tumors appeared aggressive, showing numerous mitotic figures and invasive growth ( Figure 5C ). Consistent with the ability of p53 to repress Nestin, most Yap/shp53-expressing tumors were also Nestin positive ( Figures 5D and 5E ). Importantly, similar tumors were produced using an orthogonal approach whereby a cre-ER transgene was substituted for the p53 shRNA and the same experiment performed using p53-floxed mice (p53fl/fl) (Figure S4B ): only animals treated with tamoxifen (to activate cre and delete p53) developed tumors, all of which were GFP positive, undifferentiated, and highly expressed Nestin ( Figures   S4C-S4E ). Together, these data demonstrate that p53 loss facilitates YAP-induced tumorigenesis by allowing dedifferentiation of adult hepatocytes into progenitor-like cells capable of malignant expansion. Thus, p53 appears to restrict cellular plasticity in response to an oncogenic stimulus.
Nestin Is Required for Tumorigenesis
Although Nestin has been considered simply a marker of stem and progenitor cells, its tight link to p53 expression in the liver raised the possibility that it plays a more active role in tumorigenesis. To test this, we injected transposons encoding YAP and p53 shRNA into murine livers together with an excess of a third EF1a-driven transposon vector that coexpresses either a Nestin or control (Renilla luciferase) shRNA with dsRED ( Figure 6A ). Expression of Yap/p53shRNA was again traced using GFP, whereas dsRED provided a surrogate marker for Nestin or Renilla shRNA expression. These combinations were introduced into mice by hydrodynamic transfection, and livers were analyzed 6 weeks later. The addition of the control dsRED-linked shRNA had no impact on the disease course induced by the Yap/shp53 combination, and multiple GFP/dsRED double-positive tumors with an undifferentiated histology were detected in the livers of recipient mice ( Figures 6A and 6B) . By marked contrast, the inclusion of two independent dsRED-linked Nestin shRNAs completely blocked tumor formation, such that the recipient livers showed no dsRED/ GFP foci, and no tumors were identified by histology ( Figure 6C ). The inhibitory effect of Nestin shRNAs on tumor formation was not merely a toxic side effect of RNAi in hepatocytes (Grimm et al., 2006) , as mice receiving dsRED-linked Nestin shRNAs without Yap and the p53 shRNA showed many dsRED-positive cells that were retained in the liver for at least 6 weeks without producing any overt liver pathology ( Figure 6D and data not shown).
p53 mutant Huh7 cells transduced with two potent independent Nestin shRNAs ( Figure S5A ) showed an accumulation of cells in G2/M phase of the cell cycle ( Figure S5C ) and an increase in phospho-H3-positive cells, indicative of impaired progression through mitosis ( Figure S5D ). Accordingly, Nestin-depleted cells were less able to form colonies when placed at low density (Figure S5B ) and displayed decreased tumorigenic potential upon injection into immunocompromised mice ( Figure S5E ). Although these results indicated that nestin is necessary for tumorigenesis of p53 mutant murine and human HCC cells, it is not sufficient: hence, retroviral transduction of Nestin cDNA into myc;p53
hepatoblasts was unable to mirror p53 loss in promoting transformation and had no additional impact on the proliferative capacity of myc;p53 À/À hepatoblasts in vitro ( Figure S5F ). Therefore, Nestin is required for the dedifferentiation and malignant expansion of p53-deficient cells and apparently contributes to tumor maintenance.
Additional Oncogenic ''Hits'' Program p53-Deficient Progenitor Tumors into HCCs or CCs
Although Nestin expression is normally restricted to a putative stem/progenitor cell compartment in the liver, our results demonstrate that deletion of p53 in hepatocytes facilitates cellular plasticity in response to Yap, leading to the generation of undifferentiated tumors with high Nestin expression. Nonetheless, tumors with a similar histology are not observed in humans, perhaps because lesions that enforce lineage specification cooperate with p53 loss during tumorigenesis. We therefore hypothesized that these undifferentiated cells might be driven to HCC or CC by enforcing Wnt or Notch pathway activation, which drive hepatocyte and cholangiocyte differentiation (Boulter et al., 2012) and are frequently activated in HCC and CC, respectively. To do this, we produced dsRED-tagged transposon vectors expressing an APC shRNA, which deregulates Wnt signaling, or the notch intracellular domain (NICD), which constitutively activates Notch signaling, and performed hydrodynamic transduction with the YAP/GFP and p53 shRNA transposons, as described above ( Figures 7A and 7D ). Histological analyses of the Yap/p53shRNA/APCshRNAtransduced livers performed 6 weeks after injection contained many epithelial tumors composed of polygonal cells growing in a solid-trabecular pattern without a desmoplastic stroma-features that are characteristic of HCC ( Figure 7A ). More detailed microscopic analysis of the same tissue also revealed small undifferentiated tumors similar to those observed in mice transduced with just YAP and shp53 ( Figure 7A, arrows) . Interestingly, the HCC-like lesions showed coexpression of GFP and dsRED, whereas undifferentiated tumor regions only expressed GFP, indicating that they did not express shAPC ( Figure 7B ). In agreement, the hepatocyte-specific marker HNF4a was expressed in the GFP/dsRED-double-positive HCC-like tumor zones and double-negative normal hepatocytes, but not in the GFP single-positive undifferentiated tumors ( Figure 7C ). Regardless of their differentiation state, all tumors expressed high Nestin levels ( Figure 7C ). Thus, APC loss can drive p53-deficient progenitor-like lesions toward those with features of hepatocyte differentiation while retaining high Nestin expression.
Coexpression of NICD with Yap and shp53 produced a markedly distinct result. Histopathological examination revealed tumors that displayed the typical ductal and papillary growth pattern and stromal involvement of CC ( Figure 7D ) and expressed GFP, mCherry, and the cholangiocyte marker HNF1b ( Figure 7E ). Despite their differentiated phenotype but consistent with CCs harboring mutant p53, these murine CCs retained high Nestin expression ( Figure 7E ). Collectively, these results demonstrate that p53, in part through repressing Nestin, restricts both cell plasticity and tumorigenesis in the liver. As a consequence, p53-deficient hepatocytes can produce tumors that adopt characteristics of distinct cell fates depending on initiating and cooperating oncogenic events.
DISCUSSION
Many studies have focused on the activity of p53 as a transcriptional activator and its target genes linked to cell-cycle arrest, apoptosis, senescence, and other antiproliferative processes (Vousden and Lane, 2007) . Here, we demonstrate that p53 acts via Sp1/3 to repress Nestin expression and that Nestin is required for p53 inactivation to promote liver tumorigenesis. Further, p53 loss enables dedifferentiation of mature hepatocytes in response to an oncogenic stimulus, leading to the expansion of malignant reprogrammed progenitor cells that are capable of acquiring features of HCC or CC upon acquiring lineage-specific oncogenic lesions. Nonetheless, these tumors retain high Nestin expression and an aspect of ''stemness'' that, in patients, is associated with a poor prognosis. Consequently, our results identify Nestin as a key player in liver carcinogenesis and have implications for p53 action in tumor suppression.
Nestin Is a Stem Cell Marker that Functionally Contributes to Liver Tumorigenesis
A direct role for Nestin in modulating liver cancer was unexpected, given its established role as a marker of stemness in neural progenitor cells and malignant gliomas Mignone et al., 2004) . Nonetheless, hints that Nestin plays a broader role in normal stem cell biology and cancer come from studies showing that nestin marks progenitor cell populations outside of the central nervous system and that its inhibition can impair the proliferation and survival of certain cancer cell lines in culture (Krupkova et al., 2010) . Though our data confirm these observations for HCC, the molecular mechanism by which Nestin contributes to liver tumorigenesis remains to be determined. Consistent with our observations, Nestin is required for cell proliferation, migration, and invasion in other contexts, for example, during neuronal cell development and in glioblastoma and lung cancer cell lines (Lu et al., 2011; Sahlgren et al., 2006; Takakuwa et al., 2013) .
Because Nestin is not normally expressed in adult hepatocytes but is induced in response to oncogenic stress, the requirement for Nestin in proliferation may reflect its ability to promote cell reorganization after mitosis in rapidly proliferating cells (Takakuwa et al., 2013) . Accordingly, our limited analysis confirms that Nestin is required for efficient progression through the G2/M phase of the cell cycle in human HCC cells. Regardless of the precise mechanism, our data indicate that Nestin is not merely a stem/progenitor cell marker but, instead, actively participates in cancer progression.
p53-Mediated Gene Repression and Tumor Suppression
Our results have implications for the biochemical properties of p53 that contribute to its action in cancer suppression. Despite intensive efforts to prove its relevance, it remains unclear whether transcriptional activation by p53 is sufficient to mediate tumor suppression (Brady et al., 2011) . In light of this conundrum, it is intriguing that p53 can also repress transcription, and consistent with its importance, p53-mediated repression of Nestin in the liver restricts cellular plasticity and limits tumorigenesis. Hence, p53 loss leads to high Nestin expression in p53 mutant tumors, and Nestin ablation impairs tumor formation.
p53 represses Nestin through an indirect mechanism that involves its ability to bind Sp1 and impair its function. Whether all p53 mutants are defective in binding Sp1 remains a topic of debate, though there is general agreement that p53 mutations disable its ability to repress Sp1 target genes (Zhang et al., 2000) . Interestingly, two other pluripotency genes-Nanog and CD44-are also repressed by p53 (Godar et al., 2008; Lin et al., 2005) , hinting toward a broader role for p53-mediated gene repression in maintaining cell identity. Although this repression is thought to result from direct p53 effects, both Nanog and CD44 have functional SP1 sites in their promoters and could be subject to SP1 antagonism by p53 as well (Wu and Yao, 2006; Zhao et al., 2013) . Beyond Nestin, p53/Sp1 represses the expression of other genes, including VEGF, IGF-1R, and hTERT, whose increased expression has been widely linked to tumorigenesis. It thus seems likely that p53 limits tumor growth by coordinating both gene activation and repression programs.
p53 Restricts Cellular Plasticity during Tumorigenesis
Our results also have ramifications for the biological properties of p53 that contribute to tumor suppression. p53 loss in the liver enables the aberrant expansion of oncogene-expressing cells. Unexpectedly, those malignant cells that do emerge have high nestin levels and thus retain some progenitor-like characteristics, suggesting that these cells might be particularly sensitive to the action of p53. Consistent with this view, p53 re-expression in p53-deficient embryonic carcinoma cells triggers differentiation (Lutzker and Levine, 1996) , and p53 loss enables myeloid progenitor cells to acquire an indefinite state of self-renewal in response to certain oncogenic events, thereby contributing to leukemogenesis. Together, these observations imply that a key function of p53 in tumor suppression involves its ability to restrict the self-renewal of multipotent progenitor cells. Indeed, the first p53 function that was described was its ability to restrict cellular immortalization (Harvey and Levine, 1991) , a process characterized by the indefinite ability of cultured cells to self-renew.
Beyond limiting the ability of premalignant cells to self-renew, our results imply that p53 can restrict their plasticity and that this property is important for its action as a tumor suppressor. Cellular plasticity is typically defined as the ability of cells to change identity through a process of dedifferentiation, differentiation, or both and contributes to regenerative processes in plants, invertebrates, and amphibians (Sugimoto et al., 2011) . Emerging data suggest that a similar potential exists in mammals, for example, as evidenced by the dedifferentiation of luminal secretory cells into basal stem cells in the mouse lung during injury repair (Tata et al., 2013) . Indeed, recent studies in mice suggest that dedifferentiation can accompany tumorigenesis and that differentiated cells can serve as the cell of origin of cancer (Friedmann-Morvinski et al., 2012; Schwitalla et al., 2013) .
Using a transgenesis method that stably expresses genes in adult hepatocytes, we found that p53 loss confers extraordinary cellular plasticity during liver tumorigenesis. Specifically, p53 suppression in hepatocytes allows dedifferentiation and the emergence of Nestin-positive progenitor cell tumors in response to Yap, an oncogene that is overexpressed in human HCC and CC and can drive hepatocellular carcinoma in mice (Dong et al., 2007) . Remarkably, such p53-deficient tumors can reacquire features of differentiated hepatocytes or even cholangiocytes with the addition of lineage-specific lesions that deregulate the Wnt and Notch pathways, respectively. Importantly, p53 loss alone confers no lineage bias per se but, instead, enables the expansion of progenitor-like cells that take on distinct cell fates through different cooperating genetic events.
Of the oncogene combinations that we analyzed, p53 loss was unique in its ability to produce tumors with features of undifferentiated progenitor cells. It seems likely that the appearance of these lesions also involves specific functions of YAP, as p53-deficient tumors driven by Myc or oncogenic K-ras acquire features of HCC and CC, respectively (Saborowski et al., 2013) . Nonetheless, irrespective of the cooperating oncogene, the resulting p53-deficient tumors acquire some progenitor-like characteristics as indicated by high Nestin expression. Perhaps these observations explain the association between p53 mutations and the presence of stem cell signatures in certain human cancers (Markert et al., 2011; Mizuno et al., 2010) and why HCC and CC, which otherwise display distinct mutational landscapes, each display high rates of p53 mutations (Nault and ZucmanRossi, 2011) .
A role for p53 maintaining cell identity by restricting plasticity during cancer is consistent with disparate observations relating p53 biology to cellular differentiation and stem cell biology. A primordial role for p53 in controlling cell plasticity in vivo has been noted during limb regeneration in the Salamander (Yun et al., 2013) . Despite little evidence that p53 contributes to normal mammalian development, enforced p53 expression triggers differentiation in certain p53-deficient tumor cells (Soddu et al., 1994) , and conversely, p53 loss has been described as a factor that promotes dedifferentiation during glioblastoma development in mice (Friedmann-Morvinski et al., 2012) . Collectively, these observations imply that p53 helps to maintain cell identity in cells encountering aberrant proliferative signals and support the emerging view that dedifferentiation can be important for the etiology of certain tumor types.
Our results are particularly intriguing in light of p53 action in limiting the epigenetic reprogramming of differentiated cells into induced pluripotent stem (iPS) cells (Hong et al., 2009; Kawamura et al., 2009; Marió n et al., 2009 ). While demonstrating a role for p53 in limiting plasticity, the cancer relevance of these observations was unknown and indeed might merely reflect a benefit due to increased proliferation in the reprogramming process (Hanna et al., 2009 ). Our studies suggest that p53 loss enables the reprogramming of differentiated hepatocytes to malignant progenitors with multilineage potential that can acquire distinct cell fates through sustaining other mutations. Though it seems likely that human liver carcinomas can arise from normal progenitor cells as well, our studies establish the importance of p53 in restricting cellular plasticity during liver carcinogenesis and define a tumorigenic path for the emergence of liver carcinomas with stem cell features and a poor prognosis.
EXPERIMENTAL PROCEDURES Animals and Treatments
The Nestin promoter-GFP mice were described before (Cheng et al., 2004) . Female, 8-to 10-week-old FVB/N mice were purchased from Charles River laboratories or Jackson laboratory. p53 fl/fl mice were obtained from our breeding colony and were maintained on a Bl6 background. The Alfp-Cre p53 fl/fl animals were described recently (Katz et al., 2012) . All animal experiments were approved by the MSKCC Institutional Animal Care and Use Committee (protocol 11-06-011).
Hydrodynamic Tail-Vein Injection For hydrodynamic tail-vein injection, a sterile 0.9% NaCl solution/plasmid mix was prepared containing 10 mg DNA of each Transposon vector together with CMV-SB13 Transpoase (1:5 ratio). Mice were injected with the 0.9% NaCl solution/plasmid mix into the lateral tail vein with a total volume corresponding 10% of body weight in 5-7 s.
Human Patient Samples
Generation of mRNA and array-CGH data from human hepatocellular carcinomas (Neumann et al., 2012) and human cholangiocellular carcinomas (Andersen et al., 2012) was previously described. Pseudo-anonymized human FFPE tissue samples from HCCs, HCC-CCCs, and CCCs were provided by the Tissue Bank of the National Center for Tumor Diseases Heidelberg (Heidelberg, Germany) and the Institute of Pathology of the Greifswald University (Greifswald, Germany). Institutional Review Board approval was obtained at participating hospitals. All specimens were classified according to established criteria (World Health Organization, Union for International Cancer Control) by experienced pathologists (D.F.T., M.E., and T. L.).
Statistical Analysis
Data are presented as mean ± SD if not otherwise stated. The Spearman rank coefficient or Fisher's exact test were used for statistical measure of association as indicted. The statistical comparison between two groups was accomplished with the two-tailed Student's t test. All statistical tests were performed using the PRISM6 software. 
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